For one of Nashville’s public companies, 2024 was a rough year. Cryoport President and CEO Jerrell Shelton attributed most of ...

Haemophilia Treatment Market Haemophilia Treatment Market Dublin, Jan. 13, 2025 (GLOBE NEWSWIRE) -- The "Haemophilia ...

Sana Biotechnology (SANA), a clinical-stage biotech company specializing in gene and cell therapies, has recently experienced ...

Dyno Therapeutics announces exercise of option by Roche for next-generation AAV vector for neurological gene therapy ...

EYLEA HD® and EYLEA® remained the U.S. anti-VEGF category leader in 2024; aggregate U.S. net product sales were $6 billion for full-year 2024, up 1% based on preliminary (unaudited) results EYLEA HD ...

The biotech plans to use the funding to advance clinical testing of an epigenetic silencing therapy it hopes could treat ...

A Durham biotech firm founded on technology built at Duke University has raised $175 million to fund clinical trials of its ...

Benefiting from technological and conceptual groundwork and positive early data, gene therapies are advancing in the clinic ...

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization ...

Common measurements for modified adeno-associated viruses (AAVs), a gene therapy delivery method, showed substantial ...

The Haslam family knew early on that their 10-year-old and 12-year-old were suffering from muscular dystrophy, but what they ...

Dec. 10, 2024 — In a single IV injection, a gene therapy targeting cBIN1 can reverse the effects of heart failure and restore heart function in a large animal model. The therapy increases the ...